Clinical trials: Chronic Kidney Insufficiency
Chronic Kidney Disease Stage 3, Anemia
Desidustat in the Treatment of Anemia in CKD
This is a phase III, multicenter, multi-country, open-label, randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anemia in patients with CKD who…
- Conditions
- Chronic Kidney Disease Stage 3, Anemia, Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5
- Trial name
- DREAM-ND (NCT04012957)
- Testing
- Desidustat Oral Tablet, Darbepoetin Alfa
- Where
- 32 sites in India
- Volunteers
- 588 people
- Sponsor
- Zydus Lifesciences Limited
Haemodialysis
Efficacy and Local Tolerability of Topically Applied Heparin on the Suitability of Newly Constructed Primary Arteriovenous Fistulas in Patients Planned for Haemodialysis
The primary objective of this study is to evaluate the effect of topically applied heparin in comparison to placebo on suitability of newly constructed primary arteriovenous fistulas in patients planned for haemodialysis at 7th…
- Trial name
- NCT01382888
- Testing
- Heparin 2,400 IU /ml Cutaneous Spray
- Where
- 3 sites in Austria
- Volunteers
- 30 people
- Sponsor
- Cyathus Exquirere Pharmaforschungsgmbh
Chronic Kidney Diseases
Chronic Kidney Disease Registry Platform Study
This is a multicenter, prospective, observational registry platform study which is designed to establish a CKD registry platform by collecting data on the demographics, etiology and staging, clinical characteristics, diagnostic…
- Trial name
- NCT06117852
- Where
- 34 sites in China
- Volunteers
- 5,000 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
The purpose of this study is to evaluate the safety, tolerability and the pharmacodynamics (PD) of AZD4144 following oral administration in participants with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney…
- Trial name
- NCT06675175
- Testing
- AZD4144
- Where
- 15 sites in United States, Bulgaria and 2 more
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Chronic Renal Insufficiency
An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
The purpose of the study is to provide pertinent information to enable decisions regarding the developability of LHW090 for use in patients with chronic renal insufficiency, including a comparison of the potential risk-benefit…
- Trial name
- NCT01846468
- Testing
- LHW090
- Where
- 2 sites in United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy
Study of BHV-1400 in IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
- Trial name
- NCT07054684
- Testing
- BHV-1400
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Biohaven Therapeutics Ltd.
Uremic Pruritus
Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
- Trial name
- NCT03281538
- Testing
- CR845
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 288 people
- Sponsor
- Cara Therapeutics, Inc.
Anemia, Chronic Kidney Disease
20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with Chronic Kidney Disease (pre-dialysis) with anemia with dosing for 20 weeks.
- Trial name
- NCT01906489
- Testing
- AKB-6548
- Where
- 47 sites in United States
- Volunteers
- 210 people
- Sponsor
- Akebia Therapeutics
End Stage Renal Disease (ESRD)
Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
To assess blood stream infections in participants using two FDA-cleared devices: ClearGuard HD end caps compared to the Tego® connector with the CurosTM for Tego disinfecting port protector.
- Trial name
- NCT02593149
- Testing
- ClearGuard HD End Cap
- Where
- United States
- Volunteers
- 1,902 people
- Sponsor
- Pursuit Vascular, Inc.
Hyperphosphatemia, Kidney Failure
EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)
The purpose of this study is to determine if calcium acetate (PhosLo) can control serum phosphorus in pre-dialysis patients with moderate to severe impairment of kidney function.
- Trial name
- NCT00211978
- Testing
- calcium acetate
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Nabi Biopharmaceuticals
Renal Dialysis, Kidney Failure, Chronic
Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2060 after intravenous (IV) administration of single and multiple doses in older adult participants with…
- Trial name
- NCT03873038
- Testing
- MK-2060
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Disease, Anemia
Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease
This is a Phase 1b, randomized, double-blinded, placebo-controlled study of CTX001 in participants with anemia and chronic kidney disease who are not on dialysis.
- Trial name
- NCT07901933
- Testing
- CTX001, Ferrous Sulfate
- Where
- 4 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Cajal Therapeutics Inc.
Chronic Kidney Disease, Diabetic Kidney Disease
A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.
In people with type 2 diabetes (T2D), the body makes insulin, but cannot use it well. This results in high blood sugar levels causing damage to the blood vessels inside the kidneys.
- Trial name
- ASSESS-CKD (NCT04661917)
- Testing
- BAY2327949
- Where
- 36 sites in Austria, Denmark and 5 more
- Sponsor
- Bayer
Chronic Kidney Disease, Type 2 Diabetes
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine.
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes, Obesity
- Trial name
- NCT06131372
- Testing
- Cagrilintide, Semaglutide
- Where
- 129 sites in United States, Argentina and 11 more
- Volunteers
- 626 people
- Sponsor
- Novo Nordisk A/S
Chronic Kidney Disease (CKD)
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.
- Trial name
- NCT02504294
- Testing
- Epoetin Hospira Arm, Standard of Care Arm, IV Iron
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 432 people
- Sponsor
- Pfizer
ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD)
AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
This Phase 3 clinical trial is the pivotal study of AP301 aiming to evaluate the efficacy and safety of AP301 for controlling serum phosphorus in chronic kidney disease receiving hemodialysis and peritoneal dialysis in Chinese…
- Conditions
- ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD), Hyperphosphatemia, Hyperphosphatemia in Chronic Kidney Disease
- Trial name
- RESPOND-1 (NCT07030595)
- Testing
- AP301, Sevelamer carbonate (Renvela®), AP301 Low Dose
- Where
- 50 sites in China
- Volunteers
- 474 people
- Sponsor
- Alebund Pharmaceuticals
Renal Insufficiency, Chronic
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)
The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
- Trial name
- NCT00048516
- Testing
- paricalcitol capsule
- Where
- 18 sites in United States, Poland
- Volunteers
- 68 people
- Sponsor
- Abbott
Multiple Myeloma
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb).
- Trial name
- DREAMM12 (NCT04398745)
- Testing
- Belantamab mafodotin
- Where
- 4 sites in Greece, South Korea
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease
Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients
The purpose of this study is to demonstrate equivalence of calcium acetate oral solution and sevelamer carbonate in maintaining serum phosphorus levels This is a phase IV, multicenter, randomized, open-label, cross-over study to…
- Trial name
- COS-002 (NCT01427907)
- Testing
- Calcium acetate oral solution (COS), Sevelamer carbonate
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Fresenius Medical Care North America
ESRD (End-Stage Renal Disease), Kidney Transplantation
Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1)…
- Conditions
- ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
- Trial name
- EXTEND (NCT07224763)
- Testing
- GGTA1 KO Thymokidney
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- United Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.